You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
泰国批准国药集团中国生物新冠疫苗注册上市
阿思达克 05-31 10:05
国药公布,集团中国生物北京生物制品研究所研发生产的新型冠状病毒灭活疫苗,注册申请已获得泰国食品药品监督管理局批准,为国药集团中国生物新冠疫苗获得的第五个国际药品认证合作组织成员国的准入许可,亦是世界范围内第六个正式注册。

此前,该疫苗已分别获得阿联酋、巴林、中国、玻利维亚、塞舌尔等国批准注册上市或附条件上市。

集团指,截至5月28日,该疫苗已在全球70个国家和地区获准注册上市或紧急使用,逾100个国家和国际组织提出采购需求,接种已覆盖196个国别人群。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account